Personalis Stock Price, News & Analysis

Personalis, Inc. (Nasdaq: PSNL) reported a record revenue of $20.9 million for Q1 2021, marking a 9% increase from $19.2 million in Q1 2020. Revenue from biopharma and other customers surged 74% to $7.7 million. The company added $162 million from a public offering, ending the quarter with $353.4 million in cash and equivalents. Despite these gains, net loss rose to $12.4 million, consistent with a net loss per share of $0.29. Outlook for Q2 2021 anticipates revenues of approximately $21.3 million and a net loss of $16 million to $17 million.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, will present at the 2021 Bank of America Healthcare Conference on May 13, 2021, at 5:00 p.m. Eastern Time. Renowned for its population sequencing and cancer genomics innovations, Personalis operates one of the largest sequencing programs globally, serving the U.S. Department of Veterans Affairs Million Veterans Program. Their ImmunoID NeXT Platform provides comprehensive molecular data on cancer and immune responses, enhancing next-generation therapy development.

Personalis, Inc. (Nasdaq: PSNL) will announce its Q1 2021 financial results on May 5, 2021, after market close. The company will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET to discuss these results and provide recent highlights. Interested participants can join the live call via phone or through the company's website. Personalis specializes in advanced genomics for cancer, serving as a key sequencing provider for major initiatives like the U.S. Department of Veterans Affairs Million Veterans Program.

Personalis, Inc. (Nasdaq: PSNL) announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2021, scheduled for April 10-15 and May 17-21, 2021.

The company will present new scientific data related to its ImmunoID NeXT platform, which enables comprehensive analysis of tumors and their immune microenvironments. Key presentations will cover topics such as HLA loss of heterozygosity, therapeutic resistance mechanisms in head and neck cancer, and antigen processing.

Personalis, Inc. (Nasdaq: PSNL) announced a collaboration with MapKure, LLC to use the Personalis NeXT Platform™ in clinical trials for BGB-3245, a next-generation B-RAF inhibitor targeting advanced solid tumors. This partnership aims to utilize the NeXT Platform for broad tumor immunogenomic profiling, facilitating the understanding of relevant biomarkers for BGB-3245. The collaboration emphasizes advanced biomarker development for improved cancer treatment. Financial details were not disclosed.

Personalis, Inc. (Nasdaq: PSNL) has appointed Dr. Woody Myers to its Board of Directors, enhancing its leadership with his extensive healthcare experience. Dr. Myers, previously with Blue Cross & Blue Shield of Arizona, has served on various boards and has a strong background in medicine and health policy. His addition is seen as a strategic move to bolster Personalis' commitment to precision medicine. Former director Patrick J. Balthrop has resigned, effective March 8, 2021. CEO John West expressed enthusiasm about Dr. Myers’ potential contributions to the company's vision.

Personalis, Inc. (Nasdaq: PSNL) reported record revenue of $20.2 million for Q4 2020, an 11% increase from Q4 2019. The company achieved a total of 45 customers for NeXT services and completed over 100,000 whole genomes under the VA MVP contract. Despite revenue growth, the net loss increased to $13.3 million from $6.6 million a year prior. The gross margin for Q4 was 30.1%, down from 36.2% in Q4 2019. For Q1 2021, revenues are expected around $20.3 million, with a projected net loss between $14.0 million and $15.0 million.

Personalis (Nasdaq: PSNL) and Natera (Nasdaq: NTRA) have launched a partnership to advance personalized oncology. Their collaboration combines Personalis’ NeXT tumor profiling with Natera’s Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease. Natera will validate Signatera assays using Personalis' data and handle commercialization. This non-exclusive agreement aims to enhance the integration of these technologies in clinical and research applications, expanding patient access to innovative cancer monitoring solutions.

Natera, Inc. (Nasdaq: NTRA) and Personalis, Inc. (Nasdaq: PSNL) have announced a partnership aimed at enhancing personalized oncology. This non-exclusive agreement integrates Personalis' NeXT tumor profiling products with Natera's Signatera ctDNA platform for monitoring treatment and assessing molecular residual disease (MRD). Natera will validate Signatera assays using tumor and normal exome data from Personalis and take charge of commercialization. The collaboration aims to improve availability and reliability of advanced cancer diagnostics.